

protein conformation, inhibitor off-rate, and receptor activity in tumor cells. *Cancer research*, 64(18), 6652-6659.

Yamamoto, S., Konishi, I., Tsuruta, Y., Nanbu, K., Mandai, M., Kuroda, H., ... & Mori, T. (1997). Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. *Gynecological Endocrinology*, 11(6), 371-381.

Yang, Q., Rasmussen, S. A., & Friedman, J. M. (2002). Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. *The Lancet*, 359(9311), 1019-1025.

Ylisirniö, S., Höyhty, M., Turpeenniemi-Hujanen, T. (2000). Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. *Anticancer Research*, 20(2B), 1311-1316.

Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with small molecule kinase inhibitors. *Nature Reviews Cancer*, 9(1), 28-39.

Zhou, Z., Apte, S. S., Soininen, R., Cao, R., Baaklini, G. Y., Rauser, R. W., ... & Tryggvason, K. (2000). Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. *Proceedings of the National Academy of Sciences*, 97(8), 4052-4057.

Zorick, T. S., Mustacchi, Z., Bando, S. Y., Zatz, M., Moreira-Filho, C. A., Olsen, B., & Passos-Bueno, M. R. (2001). High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. *European Journal of Human Genetics*, 9(11), 811-814.